Every 424B that Iveda Solutions, Inc. (IVDA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow IVDA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IVDA filings page.
Iveda Solutions, Inc. files a Prospectus Supplement No. 14 dated April 1, 2026 that updates its August 30, 2022 prospectus to include the company’s Annual Report on Form 10-K for the period ended December 31, 2025 (filed March 31, 2026). The supplement covers registration language for 138,759 shares of common stock, warrants to purchase up to 411,185 shares of common stock at an exercise price of $11.20, and pre-funded warrants to purchase up to 273,685 shares of common stock, and incorporates the Form 10-K by reference.
The supplement is qualified by reference to the underlying prospectus and is intended to be read together with it, including its "Risk Factors" section. This document does not itself change offering terms; it adds the Form 10-K information to the existing prospectus package.
Iveda Solutions, Inc. files a Prospectus Supplement No. 14 to the March 31, 2022 prospectus to include its Form 10-K and to cover warrants to purchase 235,625 shares of common stock at a strike price of $34.00 per share held by stockholders identified in the prospectus.
Iveda Solutions, Inc. registers primary securities for sale. The prospectus supplement registers 5,259,999 shares of Common Stock, up to 5,714,286 Series X Warrants to purchase up to 11,428,572 shares of Common Stock, and up to 400,000 Placement Agent Warrants to purchase up to 400,000 shares. The supplement incorporates the company's Form 10-K for the period ended December 31, 2025 and updates the Prospectus effective February 9, 2026.
Iveda Solutions, Inc. is conducting a primary offering of 5,259,999 shares of common stock and pre-funded warrants to purchase up to 454,287 shares, together with 5,714,286 Series X Warrants to buy up to 11,428,572 shares, plus 400,000 placement agent warrants. The common stock and Series X Warrants are priced at $0.35 per share-and-warrant unit, with pre-funded units priced at $0.3499, for total gross proceeds of $1,999,971 and estimated net proceeds of $1,859,971 before expenses. Each Series X Warrant is exercisable immediately at $0.35 per share for two years, and each pre-funded warrant is exercisable at $0.0001 per share until fully exercised. Common shares outstanding are expected to increase from 5,879,741 to 11,139,740 after the stock issuance, excluding warrant exercises. The company plans to use proceeds for general corporate purposes, including software R&D, working capital, debt repayment, capital spending, acquisitions and other corporate initiatives, while warning of significant risks including going concern doubts, continued losses, customer concentration, Taiwan exposure and potential Nasdaq delisting if listing standards are not maintained.
Iveda Solutions, Inc. (IVDA) filed a prospectus supplement registering up to 1,296,876 shares of common stock issuable upon exercise of outstanding Series A, Series B and placement agent warrants. Alongside this, the company reported Q3 2025 revenue of $1.65 million, down from $2.40 million a year earlier, but narrowed its net loss to $221,304 from $581,373 as gross margin improved. For the nine months ended September 30, 2025, revenue rose to $4.65 million from $4.28 million and the net loss improved to $1.58 million from $2.47 million, helped by lower operating expenses. Cash, restricted cash and equivalents totaled $3.33 million at period end, and Iveda subsequently raised $2.22 million of additional equity via its at-the-market program. Despite these improvements, management and the auditor concluded that recurring losses and negative operating cash flow raise substantial doubt about the company’s ability to continue as a going concern.
Iveda Solutions, Inc. (IVDA) filed a prospectus supplement that updates an existing resale registration covering warrants to purchase 411,185 shares of common stock and pre-funded warrants to purchase 273,685 shares of common stock, incorporating its latest Quarterly Report on Form 10-Q for the period ended September 30, 2025.
For the nine months ended September 30, 2025, Iveda generated total revenue of $4.65 million, up from $4.28 million a year earlier, with most sales coming from Taiwan government and commercial customers. The company reduced its net loss to $1.58 million from $2.47 million, and total stockholders’ equity increased to $3.77 million, helped by equity issuances including at-the-market sales. Cash, restricted cash and equivalents were $3.33 million at period end, and an additional $2.22 million was raised in October 2025.
Despite these improvements, management and the auditors state that recurring losses, negative operating cash flow and an accumulated deficit of $54.76 million raise substantial doubt about Iveda’s ability to continue as a going concern.
Iveda Solutions, Inc. is updating a prospectus covering warrants to purchase 235,625 shares of common stock at $34.00 per share, by incorporating its latest Form 10-Q. For the quarter ended September 30, 2025, revenue was $1.65 million, down from $2.40 million a year earlier, but the net loss narrowed to $0.22 million from $0.58 million as operating expenses fell. For the nine-month period, revenue rose to $4.65 million from $4.28 million and the net loss improved to $1.58 million from $2.47 million.
Cash, restricted cash and equivalents were $3.33 million, supported by equity raises including 1,599,383 shares sold through an at‑the‑market program for net proceeds of $2.71 million, plus an additional 1,373,809 shares in October 2025 for $2.22 million. Despite these financings and improved results, the company reports an accumulated deficit of $54.76 million and states that there is substantial doubt about its ability to continue as a going concern.